Trial Search Results

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seagen Inc.

Stanford Investigator(s):


  • Drug: SGN-35
  • Drug: gemcitabine


Phase 1


Inclusion Criteria:

   - Histologically confirmed CD30-positive hematologic malignancy.

   - Patients with HL must have failed systemic chemotherapy.

   - Patients with other CD30-positive malignancies (including ALCL) must be beyond first
   remission or refractory to front line chemotherapy.

   - Patients must have measurable disease of at least 1.5 cm as documented by radiographic

Exclusion Criteria:

   - Current diagnosis of primary cutaneous ALCL (systemic ALCL eligible).

   - History of allogeneic stem cell transplant.

   - Patients who have had previous treatment with any anti-CD30 antibody.

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Euodia Jonathan
Not Recruiting